Dyne Therapeutics (DYN) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dyne Therapeutics (DYN) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 14.5% versus a loss of 31.3%. Over five years, NAMS leads with a +126.0% price change compared with +7.3% for DYN. Dyne Therapeutics is the larger company by market cap ($2.98 billion vs $2.59 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYN | NAMS |
|---|---|---|
| Share price | $15.97 | $22.13 |
| Market cap | $2.98B | $2.59B |
| 1-day change | +3.70% | -0.63% |
| YTD return | -18.35% | -36.92% |
| 1-year return | +14.48% | -31.29% |
| 5-year return | +7.33% | +126.05% |
| EPS (TTM) | $-3.42 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $22.50M |
| Revenue growth (YoY) | — | -50.61% |
| Net income (latest FY) | $-446.21M | $-203.82M |
| Operating margin | — | -1002.90% |
| Net margin | — | -905.74% |
| 52-week high | $27.31 | $42.21 |
| 52-week low | $13.73 | $21.02 |
| Distance from 52-week high | -41.51% | -47.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +125.42% | +124.36% |
| Average volume | 2.77M | 1.35M |
| Shares outstanding | 186.75M | 116.90M |
| Employees | 289 | 100 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYN has outperformed NAMS by 45.8 percentage points over the past year.
- The two companies sit in different sectors: Dyne Therapeutics in Health Care and NewAmsterdam Pharma N.V. in Healthcare.
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 289 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Healthcare · Biotechnology · 100 employees
DYN vs NAMS FAQ
Which is bigger, Dyne Therapeutics or NewAmsterdam Pharma N.V.?
Dyne Therapeutics (DYN) is larger, with a market capitalization of $2.98B compared with $2.59B for NewAmsterdam Pharma N.V. (NAMS).
Which stock has performed better over the past year, DYN or NAMS?
DYN returned +14.48% over the past 12 months, compared with -31.29% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are Dyne Therapeutics and NewAmsterdam Pharma N.V. in the same industry?
No. Dyne Therapeutics is in the Health Care sector, while NewAmsterdam Pharma N.V. is in Healthcare.